产品名称 |
M059J人脑恶性胶质母细胞瘤细胞 |
货号 |
ZQ1196 |
产品介绍 |
M059J 是从一名 33 岁男性恶性胶质母细胞瘤患者的大脑中分离出来的胶质细胞。这些细胞系提供了有用的模型系统,可用于研究 DNA 蛋白激酶在涉及 DNA 损伤识别和修复的细胞和分子过程中的作用。它可用于神经科学研究。 M059J 细胞缺乏 DNA 依赖性蛋白激酶活性,而 M059K 细胞表达正常水平的 DNA 依赖性蛋白激酶。M059J 细胞对电离辐射的敏感性比 M059K 细胞高约 30 倍。M059J 细胞比 M059K 细胞对博来霉素、N,N-双(2-氯乙基)-N-亚硝基脲和氮芥的细胞毒性作用更敏感。M059J 细胞缺乏 DNA 双链断裂修复能力。这些细胞的神经胶质原纤维酸性蛋白 (GFAP) 呈阴性。 |
种属 |
人 |
性别/年龄 |
男,33岁 |
组织 |
脑 |
疾病 |
胶质母细胞瘤 |
细胞类型 |
肿瘤细胞系 |
形态学 |
成纤维细胞样 |
生长方式 |
贴壁 |
倍增时间 |
*** |
培养基和添加剂 |
DMEM/F12(中乔新舟 货号:ZQ-600) +10%胎牛血清(中乔新舟 货号:ZQ500-A)+1%P/S(中乔新舟 货号:CSP006)+1% Sodium Pyruvate 100 mM Solution(中乔新舟 货号:CSP003)+1%Non-essential Amino Acids, 100X (中乔新舟 货号:CSP008) |
推荐完全培养基货号 |
ZM1196 |
生物安全等级 |
BSL-1 |
培养条件 |
95%空气,5%二氧化碳;37℃ |
STR位点信息 |
Amelogenin :X (PubMed=25877200) X,Y (ATCC=CRL-2366; Cosmic-CLP=949094) CSF1PO: 10 (PubMed=25877200) 10,12 (ATCC=CRL-2366; Cosmic-CLP=949094) D2S1338: 20,24 D3S1358: 14 (PubMed=25877200) 14,15 (ATCC=CRL-2366) D5S818: 11,12 (ATCC=CRL-2366; Cosmic-CLP=949094) 12 (PubMed=25877200) D7S820: 10 (PubMed=25877200) 10,12 (ATCC=CRL-2366; Cosmic-CLP=949094) D8S1179: 15 D13S317: 14 D16S539: 10,12 D18S51: 15,19 D19S433: 14 D21S11: 30,31.2 FGA :20 Penta D :12,13 Penta E: 7 TH01: 9.3 TPOX: 8 vWA: 17 |
抗原表达/受体表达 |
*** |
基因表达 |
*** |
保藏机构 |
ATCC; CRL-2366 BCRC; 60382 BCRJ; 0151 |
供应限制 |
仅供科研使用 |
货号 |
ZQ1196 |
发货规格 |
活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一 |
发货形式 |
活细胞:常温运输;冻存管:干冰运输 |
储存温度 |
活细胞:培养箱;冻存管:液氮罐 |
产地 |
中国 |
供应限制 |
仅供科研使用 |
PubMed=8316628; DOI=10.2307/3578196
Allalunis-Turner M.J., Barron G.M., Day R.S. 3rd, Dobler K.D., Mirzayans R.
Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs.
Radiat. Res. 134:349-354(1993)
PubMed=7494872; DOI=10.2307/3578948
Allalunis-Turner M.J., Zia P.K.Y., Barron G.M., Mirzayans R., Day R.S. 3rd
Radiation-induced DNA damage and repair in cells of a radiosensitive human malignant glioma cell line.
Radiat. Res. 144:288-293(1995)
PubMed=10629611; DOI=10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2
Hoppe B.S., Jensen R.B., Kirchgessner C.U.
Complementation of the radiosensitive M059J cell line.
Radiat. Res. 153:125-130(2000)
PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:HTFTMG]2.0.CO;2
Anderson C.W., Allalunis-Turner M.J.
Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8.
Radiat. Res. 154:473-476(2000)
PubMed=11418067; DOI=10.1667/0033-7587(2001)156[0002:FMIPTG]2.0.CO;2
Anderson C.W., Dunn J.J., Freimuth P.I., Galloway A.M., Allalunis-Turner M.J.
Frameshift mutation in PRKDC, the gene for DNA-PKcs, in the DNA repair-defective, human, glioma-derived cell line M059J.
Radiat. Res. 156:2-9(2001)
PubMed=12105990; DOI=10.1667/0033-7587(2002)158[0195:DOAGMI]2.0.CO;2
Tsuchida R., Yamada T., Takagi M., Shimada A., Ishioka C., Katsuki Y., Igarashi T., Chessa L., Delia D., Teraoka H., Mizutani S.
Detection of ATM gene mutation in human glioma cell line M059J by a rapid frameshift/stop codon assay in yeast.
Radiat. Res. 158:195-201(2002)
PubMed=18757420; DOI=10.1158/0008-5472.CAN-08-0545; PMCID=PMC2528059
Burdak-Rothkamm S., Rothkamm K., Prise K.M.
ATM acts downstream of ATR in the DNA damage response signaling of bystander cells.
Cancer Res. 68:7059-7065(2008)
PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)
PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)
PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)
PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)